Cargando…

A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea

In clinical practice, most patients with monoclonal gammopathy of undetermined significance (MGUS) undergo long-term follow-up without disease progression. There is insufficient real-world data about how closely and whether anything other than disease progression should be monitored. Herein, we perf...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Ka-Won, Song, Ji Eun, Lee, Byung-Hyun, Jeon, Min Ji, Yu, Eun Sang, Kim, Dae Sik, Lee, Se Ryeon, Sung, Hwa Jung, Choi, Chul Won, Park, Yong, Kim, Byung Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445957/
https://www.ncbi.nlm.nih.gov/pubmed/34531426
http://dx.doi.org/10.1038/s41598-021-97664-y
_version_ 1784568769508540416
author Kang, Ka-Won
Song, Ji Eun
Lee, Byung-Hyun
Jeon, Min Ji
Yu, Eun Sang
Kim, Dae Sik
Lee, Se Ryeon
Sung, Hwa Jung
Choi, Chul Won
Park, Yong
Kim, Byung Soo
author_facet Kang, Ka-Won
Song, Ji Eun
Lee, Byung-Hyun
Jeon, Min Ji
Yu, Eun Sang
Kim, Dae Sik
Lee, Se Ryeon
Sung, Hwa Jung
Choi, Chul Won
Park, Yong
Kim, Byung Soo
author_sort Kang, Ka-Won
collection PubMed
description In clinical practice, most patients with monoclonal gammopathy of undetermined significance (MGUS) undergo long-term follow-up without disease progression. There is insufficient real-world data about how closely and whether anything other than disease progression should be monitored. Herein, we performed a nationwide study of 470 patients with MGUS with a 10-year follow-up to determine the patterns of disease progression and other comorbidities. During the follow-up period, 158 of 470 patients with MGUS (33.62%) progressed to symptomatic monoclonal gammopathies. Most of these were multiple myeloma (134/470 patients, 28.51%), and those diagnosed within 2 years after diagnosis of MGUS was high. Approximately 30–50% of patients with MGUS had hypertension, diabetes, hyperlipidemia, and osteoarthritis at the time of diagnosis, and these comorbidities were newly developed during the follow-up period in approximately 50% of the remaining patients with MGUS. Approximately 20–40% of patients with MGUS have acute or chronic kidney failure, thyroid disorders, disc disorders, peripheral neuropathy, myocardial infarction, stroke, and heart failure during the follow-up period. Altogether, when MGUS is diagnosed, close follow-up of the possibility of progression to multiple myeloma is required, especially within 2 years after diagnosis; simultaneously, various comorbidities should be considered and monitored during the follow-up of patients with MGUS. Continuous research is needed to establish appropriate follow-up guidelines.
format Online
Article
Text
id pubmed-8445957
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-84459572021-09-20 A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea Kang, Ka-Won Song, Ji Eun Lee, Byung-Hyun Jeon, Min Ji Yu, Eun Sang Kim, Dae Sik Lee, Se Ryeon Sung, Hwa Jung Choi, Chul Won Park, Yong Kim, Byung Soo Sci Rep Article In clinical practice, most patients with monoclonal gammopathy of undetermined significance (MGUS) undergo long-term follow-up without disease progression. There is insufficient real-world data about how closely and whether anything other than disease progression should be monitored. Herein, we performed a nationwide study of 470 patients with MGUS with a 10-year follow-up to determine the patterns of disease progression and other comorbidities. During the follow-up period, 158 of 470 patients with MGUS (33.62%) progressed to symptomatic monoclonal gammopathies. Most of these were multiple myeloma (134/470 patients, 28.51%), and those diagnosed within 2 years after diagnosis of MGUS was high. Approximately 30–50% of patients with MGUS had hypertension, diabetes, hyperlipidemia, and osteoarthritis at the time of diagnosis, and these comorbidities were newly developed during the follow-up period in approximately 50% of the remaining patients with MGUS. Approximately 20–40% of patients with MGUS have acute or chronic kidney failure, thyroid disorders, disc disorders, peripheral neuropathy, myocardial infarction, stroke, and heart failure during the follow-up period. Altogether, when MGUS is diagnosed, close follow-up of the possibility of progression to multiple myeloma is required, especially within 2 years after diagnosis; simultaneously, various comorbidities should be considered and monitored during the follow-up of patients with MGUS. Continuous research is needed to establish appropriate follow-up guidelines. Nature Publishing Group UK 2021-09-16 /pmc/articles/PMC8445957/ /pubmed/34531426 http://dx.doi.org/10.1038/s41598-021-97664-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Kang, Ka-Won
Song, Ji Eun
Lee, Byung-Hyun
Jeon, Min Ji
Yu, Eun Sang
Kim, Dae Sik
Lee, Se Ryeon
Sung, Hwa Jung
Choi, Chul Won
Park, Yong
Kim, Byung Soo
A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea
title A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea
title_full A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea
title_fullStr A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea
title_full_unstemmed A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea
title_short A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea
title_sort nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in south korea
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445957/
https://www.ncbi.nlm.nih.gov/pubmed/34531426
http://dx.doi.org/10.1038/s41598-021-97664-y
work_keys_str_mv AT kangkawon anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea
AT songjieun anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea
AT leebyunghyun anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea
AT jeonminji anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea
AT yueunsang anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea
AT kimdaesik anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea
AT leeseryeon anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea
AT sunghwajung anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea
AT choichulwon anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea
AT parkyong anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea
AT kimbyungsoo anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea
AT kangkawon nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea
AT songjieun nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea
AT leebyunghyun nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea
AT jeonminji nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea
AT yueunsang nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea
AT kimdaesik nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea
AT leeseryeon nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea
AT sunghwajung nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea
AT choichulwon nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea
AT parkyong nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea
AT kimbyungsoo nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea